Enfortumab vedotin
product
3 mentions
2 recordings
first heard Oct 2025
last heard 17 Feb
↑3 vs the 12 months before
Enfortumab vedotin, a nectin‑4 ADC owned by Pfizer
Trend
Peak in the week of 13 Feb — 2 mentions across 1 series.
Moments
newest first · ▶ plays the momentDr. Abhinav KhannaBackTable Urology · Ep. 290 Urothelial Carcinoma: Consolidative Surgery & Treatm... · 3:40 · 17 Feb
…So the EB302 trial came out a couple of years ago, showed that infortimab vedotin is just so much more effective than infortimab vedotin plus pembrolizumab, so much more effective than traditional cisplatin-based chemotherapy, and really overnight became the standard of care.…
Dr. Daniel RobersonBackTable Urology · Ep. 290 Urothelial Carcinoma: Consolidative Surgery & Treatm... · 1:21 · 17 Feb
…We're going to be talking about consolidative surgery in patients who have advanced urothelial carcinoma and who have received induction antibody drug conjugate therapy and immunotherapy, more specifically, infortimab, vedotin, and pembrolizumab.…
Sam FazeliVanguards of Healthcare by Bloomberg Intelligence · Recapping ESMO, Inside AstraZeneca’s Bold Bet on Antibody ... · 46:51 · 27 Oct
…And which was infortimab vedotin, which is a nectin-4 ADC that now is owned by Pfizer, plus Keytruda pembrolizumab.…
All 3 moments